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Abstract 
Several pharmacoepidemiology networks have been developed over the past decade that use a 
distributed approach, implementing the same analysis at multiple data sites, to preserve privacy 
and minimize data sharing.  The structure of these networks can also be leveraged to improve 
replicability, increase transparency, and reduce bias.  We describe some features of distributed 
networks using, as examples, the Canadian Network for Observational Drug Effect Studies, the 
Sentinel System in the USA and the European Research Network of Pharmacovigilance and 
Pharmacoepidemiology. Common protocols, analysis plans, and data models, with policies on 
amendments and protocol violations, are key features.  These tools ensure that studies can be 
audited and repeated as necessary. Blinding and strict conflict of interest policies reduce the 
potential for bias in analyses and interpretation. Distributed networks are efficient, by 
interrogating data on very large populations. These developments should improve the timeliness 
and accuracy of information used to support both clinical and regulatory decisions. 
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Introduction 
Bias is the pervasive threat to observational pharmacoepidemiology. Confounding, selection 
bias, and measurement error can arise in any observational study, and confounding by indication 
and protopathic bias are common in studies of drug effectiveness and safety. This is one of the 
reasons why regulators favor randomized trials as the primary source of evidence for drug 
approval. But randomized trials are costly and their ability to quantify adverse effects is often 
limited by insufficient sample size and duration of follow-up. Consequently, observational 
studies have become a cornerstone of drug safety research. Considerable gains have been made 
in the development of design and analytical methods to minimize biases in pharmaco-
epidemiological research (1). These developments are recognized by regulators; for example, 
21st Century Cures Act in the United States supports the use of observational data to support new 
drug indications and post-marketing requirements (2), while the EMA scientific guide on post-
authorisation studies clearly indicates openness to observational studies for investigating post-
authorisation issues (3). 
 
Timeliness, replicability, reproducibility, and transparency are important in ensuring confidence 
in decisions based on research studies (4,5). Replicability and transparency are particularly 
important in drug safety, where study results may lead directly to regulatory and public health 
action. Divergence in study results  can create significant uncertainty for patients, practitioners, 
drug manufacturers, and regulators (6).  There are multiple examples of “one-off” studies, where 
the findings have not been replicated. Sometimes this indicates true variability, but more often it 
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is attributable to methodological variation between studies (7) and lack of transparency.  It is 
often not possible to discern the underlying cause of these differences. Observational studies 
have been increasingly used to investigate new indications for older drugs, including hormone 
replacement therapy to prevent cardiovascular disease, statins to treat chronic obstructive 
pulmonary disease (COPD) and metformin to treat cancer (8,9).  These hypotheses were refuted 
in subsequent randomized trials and the observational studies were found to have important 
methodological weaknesses (10,11) further indicating the need for minimally biased and 
reproducible observational studies  While there are well-established procedures for Good 
Clinical Practice for the conduct of randomized trials, these procedures are less standardized for 
observational studies. For example, pharmacovigiliance studies in the European Union should 
follow analogous Good Pharmacovigilance Practices, and may be subject to routine inspections. 
 
 
Data networks are highly efficient, and with distributed analyses they effectively implement the 
same study at multiple sites (12). Distributed analyses, using near-identical protocols, can assure 
methodological quality and transparency, and increase the likelihood that differences between 
sites are due to true variation in effect size, rather than design or process-related problems.  
Moreover, study designs developed by teams help ensure that errors are not overlooked, and 
should be more likely to avoid known errors and minimize bias. Nevertheless, while study 
methods are the primary focus of efforts to minimise bias, network operations offer additional 
opportunities to improve study quality.  
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In this commentary we focus on management approaches to minimisation of bias in network 
analyses other than good study design and methods.  We illustrate these principles in the context 
of work by three distributed pharmacoepidemiology networks: Sentinel, The Canadian Network 
for Observational Drug Effect Studies (CNODES), and the European Pharmacoepidemiology 
and Pharmacovigilance Research Network (formerly IMI-PROTECT). 
Phased Common Protocol-driven Analyses 
One of the strengths of the randomized trial paradigm is the requirement for detailed protocols 
and statistical analysis plans. These are typically followed carefully, across multiple sites, with 
documentation of any amendments and protocol deviations. This ensures that the study 
accomplishes what was intended, and that others can replicate the study setting and results if 
necessary.   
Distributed networks enable similar protocol-driven analyses of observational data at multiple 
sites. As an example, CNODES conducts studies using a structured protocol, along with a very 
detailed data management and statistical analysis plan, to ensure that processes are comparable 
(ideally, identical) in the various study sites, and that others can follow and validate these 
processes. The guiding principles of this process are reproducibility and bias minimization.  The 
intent is that any potential biases or problems in the data are discovered before any decision is 
made on the drug-outcome association, and that any analyses done in one center could be 
reproduced if another analyst were given the same data and the statistical analysis plan. 
At CNODES protocols are developed in a collaborative way involving several researchers and 
stakeholders, to ensure that multiple inputs are considered, and no group or perspective 
dominates the discussion. CNODES protocols are registered with clinicaltrials.gov, with clearly 
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specified outcomes and exposures (including description of codes and measures used to define 
them). Protocol amendments, deviations and outlying results are monitored and recorded and 
registered, increasing the likelihood that the process is reproducible. Similarly, all study 
protocols of the IMI-PROTECT network were registered at the European Union electronic 
Register of Post-Authorization Studies (EU-PAS Register), available at the website of the 
European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) 
(www.encepp.eu). 
The statistical analysis plan (SAP) is a key component of CNODES’ process.  This is a step-by-
step guide that sets out how each CNODES site will design their study and analyze their data. It 
is usually written after the scientific protocol has been developed by the project team in 
consultation with site investigators and analysts, who must ensure the feasibility of the work at 
the participating sites.  The statistical analysis plan includes detailed descriptions, including SAS 
code for complex analyses of primary outcomes, as well as detailed sensitivity analysis.  
The SAP is created and implemented in phases. The first phase describes cohort construction, 
including definitions of exposures, outcomes, and measures of confounding, and requires 
production of descriptive statistics.  These descriptive statistics are reviewed before proceeding 
with further analyses, to ensure that the initial assumptions (e.g. outcome frequencies and 
distributions of potential confounders) on which the study was based were valid, and that data 
are roughly comparable across sites. For example, Renoux et al (13) detected a nine-fold 
difference between sites in the rate of coding of sudden cardiac death after reviewing initial data. 
These processes enable judgement on the feasibility of the study, and on appropriateness of 
confounding control at an early stage in the research. Importantly, they allow the research team 
to understand comparability of the data before any analyses of association are conducted. Any 
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comparisons across sites after associations are computed may be subject to the biases mentioned 
above; comparing only baseline data preserves the statistical properties of the estimation process 
so that, for example, 95% confidence intervals have appropriate 95% coverage. 
The second phase of the analysis includes models for the primary analysis as well as secondary 
and sensitivity analyses.  These analyses are conducted only after review of initial results by the 
research team and by the query submitter.  As above, any protocol deviations or amendments are 
recorded.  The analyses are then deposited in a secure repository for review by the central team. 
When site teams lodge results, they are unaware of the data that have been lodged by other sites 
(see section on Blinding). 
Both Sentinel and CNODES separate the work done by the analysis teams (conducting analyses 
at individual sites) and the group that conducts the summary analyses and meta-analyses. The 
independent scrutiny of site-specific results sometimes identifies outliers.  CNODES uses a 
structured process for investigating these.  A series of structured quality checks are initiated by 
the analysis team to determine whether there were any errors in coding, and further follow up is 
done to assess whether population or formulary differences may account for the results.  This has 
occurred in few CNODES studies to date.  In one study, an outlier was identified, but re-analysis 
and follow-up determined that the analyses were done correctly and that there were no obvious 
reasons for the outlier (14); in a second study, an outlier was identified and was eventually 
ascribed to differences in formulary restrictions across provinces (15). 
Common Data Model-based Methods 
Sentinel uses a similar process to CNODES but focuses on a common data model (16) and 
standardized analytic programs (17,18). The Sentinel common data model (SCDM) is a 
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framework in which data are converted to a standardized data structure with common table 
formats, meanings, and variable names across data partners. The SCDM primarily preserves 
original data values, such as diagnosis or procedure codes, whenever possible, so that few values 
are mapped, combined or manipulated in the conversion process to minimize information is lost; 
in principle the data could be converted back to the original dataset.  The data model 
transformations are subjected to rigorous review and data are only used when each dataset has 
passed the Sentinel data quality review process (19) 
 
Some Sentinel system studies begin with a detailed protocol that serves as the basis for a single 
team to developing analytic programs. A set of standardized SAS programs is then distributed to 
the sites, who run the analyses without modification and return only summary results to the 
coordinating center via a secure portal.  Full protocols are publicly posted (20). Full reports are 
also publicly posted (21) and published when appropriate (22).  
 
Increasingly, Sentinel employs reusable “modular” programs in place of custom written 
programs to perform commonly needed analyses, such as propensity score matched new user 
comparative cohort studies and self-controlled risk interval studies. These programs have the 
advantage of much faster development time, execute more efficiently than one off programs, and 
they obviate the need for detailed review at each site. These modular programs form the basis for 
FDA’s Active Risk Identification and Analysis (ARIA) program. When an ARIA analysis study 
is initiated, a study concept brief is used to develop a set of query specifications that are used by 
the standardized SAS tools to implement the specific query.  Several aspects of Sentinel 
processes minimize the potential for bias.  Most of the processes are like those used by 
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CNODES.  In addition, since the distributed programs require that data structures and software 
are identical across sites, inter-analyst discrepancies are effectively eliminated.   
 
Other networks have used variations on each of these systems. The Observational Health Data 
Sciences and Informatics (OHDSI) network uses the Observational Medical Outcomes 
Partnership (OMOP) common data model, which has aspects like the SCDM but with some key 
differences.  The major difference is that the OMOP CDM maps the raw data to concepts; drugs, 
conditions, and outcomes are defined using summary concepts rather than the individual data 
elements; these concepts are the basis of the analyses. OMOP is also an open-source framework 
(23), so that quality checks are the responsibility of the individual sites rather than based on a 
centralized and standardized approach that determines acceptable levels of data quality, data 
model conformance to value sets, format, and meaning before use.  The AsPEN network (24)  
has implemented the OMOP CDM. In contrast, the IMI-PROTECT network used a common-
protocol method similar to CNODES (25).   
Which of these strategies is better or more useful? It depends on the question and the setting.  
Common data model and protocol-based methods are clearly more likely to be replicated across 
network sites, because they reduce the amount of variation between datasets and data analysts. 
The Sentinel CDM standardizes data structures and is actively curated; data must be reviewed 
and approved before use in any analyses. The OMOP CDM takes one step further by mapping 
standard coding terminologies to standardize definitions.  Both methods require significant up-
front development work, which pays off based on economies of scale. Further, the use of 
standardized programs potentially limits the kinds of analyses that could be done quickly using 
the tools, but may increase transparency of results by reducing ambiguity about the methods. The 
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combination of a CDM and standardized tools enables transparent representation of the analysis, 
including sharing the detailed standardized specifications and even the executable code. Each 
Sentinel report is posted to the Sentinel website (https://www.sentinelinitiative.org/) and includes 
the detailed study specifications used by the standardized SAS tools, thereby allowing full 
transparency and greatly facilitating reproducibility.   
Blinding 
In clinical studies, in particular randomized controlled trials, it is standard practice to blind 
evaluators to the treatment status of the patient so as to avoid bias in the evaluation of patient 
outcomes (26).  Sentinel, by using distributed SAS code, and centralized result collection, 
ensures that data partner-specific results are not seen by other data partners or any other 
stakeholders prior to final reporting of results. Only the central team sees all results before 
aggregation and final analysis. Further, because the results are aggregated based on the pre-
determined study specifications, the potential for post hoc analyses is greatly reduced and often 
impossible given the data available to the central team. 
Blinding is particularly relevant when there are differential delays in analyses across sites. 
Typically, these are due to the timing of approval by different data custodians.  If one site in the 
network is delayed, and other sites have already submitted results, the analyst could feel some 
obligation to make decisions leading to a result that is consistent with those already lodged. To 
prevent this possibility, CNODES analysts are advised not to discuss results amongst themselves 
prior to discussion of the complete pooled results.  Analyses are deposited in a centralized 
repository, such that site researchers can only see their own results, and only the central analysis 
team has access to all sites’ results.  These blinding steps ensure that analysts don’t have the 
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opportunity to “chase” results, i.e., to try to manipulate their own results to resemble other sites, 
and that each analysis is done in compliance with the protocol. The IMI-PROTECT network 
applies a similar approach.  Analysts in participating centres are blinded to the results of the 
other centres and results are stored at the coordinating centre. After completion of analyses by all 
centres, results are shared and discussed (27). 
Conflicts of Interest 
In studies of drug safety, conflict of interest (COI) is a potential source of bias. COI can arise 
when interests of a personal, financial, or other nature (e.g., ownership of, or consulting for, a 
pharmaceutical company that manufactures a treatment under consideration) may impact 
impartiality with respect to a particular study. Complete avoidance of COI is hard to achieve 
across a network comprising researchers with expertise in clinical sciences, epidemiology and 
biostatistics. Thus, large teams conducting network analyses must manage potential conflicts.  
The CNODES executive committee conducts an annual review of disclosures provided by all 
steering committee members and analysts; in addition, a study-specific disclosure is required 
from each study team member.  The CNODES policy (28) specifies conflicts of interest that 
preclude participation in CNODES studies, and provides principles for managing other, less 
serious, conflicts.  Briefly, a researcher with a significant conflicting interest relating to a 
specific drug, or topic, cannot lead or provide substantial input into a CNODES study. If a 
conflicted researcher has relevant knowledge or skills (e.g. clinical content), input may be 
sought, but a management strategy is implemented. For instance, the researcher me be involved 
in the design phase, and qualify as co-author, but is not involved directly in the analysis or 
reporting of the study. Sentinel has a similar detailed policy to manage conflicts of interest. It 
requires that individuals who are in decision-making roles regarding analyses not have conflicts 
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of interest. The IMI-PROTECT project was a public-private partnership and the initial studies 
were methodological case-studies on relevant drug safety issues that were known. In the EU 
Pharmacoepidemiology & Pharmacovigilance Research Network the public partners have 
continued their collaboration via a framework contract with the European Medicines Agency 
(EMA) (29) All studies are conducted according to the ENCePP Code of Conduct in which a set 
of rules and principles for pharmacoepidemiology and pharmacovigilance studies are provided to 
promote transparency and scientific independence throughout the research process (30).  
 
Table 1 summarizes the three networks’ approaches to each of these issues. 
Conclusion 
Bias and lack of replicability are constant threats to drug safety research. Best practices in study 
design and analysis, particularly when developed in a team environment, can avoid known 
errors, minimize bias, and increase replicability of findings across individually conducted 
studies.  Moreover, distributed data networks are uniquely positioned to address these problems 
through procedures and processes such as those outlined here.  Strict procedures for collaborative 
design, and careful attention to protocol development and implementation can help minimize 
bias; the use of distributed networks inherently ensures replicability, given that studies are 
conducted concurrently at multiple sites.  
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Table 1:  
 
Network Protocol-
driven 
analysis 
Common data 
model 
Blinding Conflict of 
Interest 
CNODES Analyses 
follow 
registered, 
pre-specified 
protocol 
Detailed 
statistical 
analysis plan 
Interim 
analyses 
None for most 
studies. 
Implementing 
Sentinel CDM 
(pilot) 
To be used for 
simple queries 
All 
analysts 
blinded to 
others’ 
results 
until 
central 
review 
complete 
COI 
managed 
following 
pre-specified 
policy 
Study-
specific and 
annual COI 
declarations. 
Sentinel Sentinel 
common data 
model 
projects 
follow pre-
specified 
protocols. 
Analyses use 
standardized 
algorithms 
Uses Sentinel 
CDM and 
distributed 
analyses 
Only 
central site 
sees all 
results 
COI 
managed 
following 
pre-specified 
policy 
IMI-
PROTECT/EnCEPP 
Analyses 
follow 
registered, 
pre-specified 
protocol. 
Protocols 
registered at 
EU-PAS 
Registry 
No common 
data model 
All 
analysts 
blinded to 
others’ 
results 
until 
central 
review 
complete 
Follows EU-
ADR 
framework. 
 
